Project Grant R01NS144449
Award Date 9/9/25
Completion Date 8/31/30
Dollars Obligated $564K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Alabama, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $559,030 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Medical University of South Carolina. The grant supports a 5-year research project to "Uncover the Signaling Mechanisms Underlying Treatment Failure in Medulloblastoma". The objective is to investigate the signaling pathways that enable certain progenitor cell populations to...
- This Project Grant award, valued at $611,591.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, aims to research new strategies to overcome therapy resistance in Hedgehog pathway-driven medulloblastoma, the most common malignant pediatric brain cancer. The key focus areas of this research project include: 1) investigating a new...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $773,607 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Johns Hopkins University. The grant supports the development of brain-penetrant, histone evicting anthracycline drugs for the treatment of diffuse midline glioma (DMG), an aggressive and incurable form of pediatric brain cancer. The researchers are working to develop novel anthracycline...
- This Project Grant award of $241,380 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to advance the understanding of neurodevelopmental disorders (NDDs) and develop innovative therapies. The research program, led by researchers at Boston Children's Hospital, will use single-cell epigenomic technologies to link pathogenic variants in chromatin regulators, such as...
- This federal Project Grant award of $604,852.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to investigate the role of glial progenitor cells in the initiation and recurrence of medulloblastoma, the most common malignant childhood brain tumor. The research aims to advance the understanding of tumor heterogeneity,...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to St. Jude Children's Research Hospital Inc. provides $718,113 to fund research on "Targetable Epigenetic Modifiers that Promote Neuroblastoma Malignancy and Plasticity". The project aims to investigate how epigenetic factors, including histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), connect the MYC oncogenes to neuroblastoma-specific...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to develop high-quality chemical probes to functionally annotate the epigenetic effector "reader" domains within the Bromodomain PHD Finger Transcription Factor (BPTF) in neuroblastoma, an aggressive pediatric cancer. The $738,024 award, effective from January 1, 2025 to December 31, 2029, aims to optimize BPTF bromodomain and plant homeodomain (PHD)...
- This $443,354 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate targeting the hexosamine biosynthetic pathway as a potential treatment for pediatric brain tumors. The research aims to understand how this metabolic pathway supports the growth and apoptosis resistance of diffuse midline gliomas with the...
- This Project Grant award for $249,417.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395) to support the development of a drug product called MT-125 for the treatment of recurrent high-grade glioblastomas (GBM). Glioblastoma is an aggressive and deadly form of brain cancer with a very poor prognosis. The award will fund preclinical studies and a Phase 0/1B dose escalation clinical trial of MT-125, a dual inhibitor of...
- The Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy and toxicity of the thyroid hormone T3 for the treatment of medulloblastoma, the most common malignant brain tumor in children. The $219,351 award to The Institute for Cancer Research will fund two specific aims: 1) evaluating the toxicity, pharmacokinetics, and pharmacodynamics of T3 in tumor-bearing mice, and 2) examining the therapeutic efficacy of T3...